---
schema_version: "secwatch.filing_event.v1"
accession: "0001842952-24-000005"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:55:22.023851+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics amends Integral license for CTIM-76 after finding potential third-party patent conflict

## Summary
- Discovered third-party patents expiring Jan 2034 may cover CTIM-76; company believes it has defenses but may not prevail.
- Amendment reduces development milestones from $55M to $15M, sales milestones from $130M to $12.5M.
- Royalty reduced from 8–12% to flat 6% on net sales, starting no sooner than February 2034.
- License narrowed to only CTIM-76; company no longer obligated to reimburse Integral for research funding.
- Deal includes mutual releases and revised milestone triggers tied to Phase 1b/2, Phase 3, and marketing approvals.

## SEC filing metadata
- accession: 0001842952-24-000005
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000184295224000005/0001842952-24-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000184295224000005/cntx-20240229.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001842952-24-000005
- JSON: https://secwatch.observer/filing/0001842952-24-000005.json
- Plain text: https://secwatch.observer/filing/0001842952-24-000005.txt

## Key facts
- Material Agreements
  Context Therapeutics Inc. amended Integral License Agreement with Integral Molecular, Inc. (effective 2024-02-29).
  - Action: amendment
  - Agreement: collaboration
  - Counterparty: Integral Molecular, Inc.
  - Effective: 2024-02-29
  source text: Context Therapeutics Inc. (the “Company”) amended its collaboration and licensing agreement with Integral Molecular, Inc. (“Integral”) (the “Integral License Agreement”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842952/000184295224000005/0001842952-24-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.